Treating iron overload in patients with non-transfusion-dependent thalassemia

American Journal of Hematology

Volumn 88, Issue 5, 2013, Pages 409-415

  Taher, Ali T ^a   Viprakasit, Vip ^b   Musallam, Khaled M ^a,c   Cappellini, M Domenica ^c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN; FERROPORTIN; GROWTH DIFFERENTIATION FACTOR 15; HEPCIDIN; IRON;

ALPHA THALASSEMIA; ANEMIA; ARTICLE; BONE MATRIX; CHELATION THERAPY; DRUG DOSE ESCALATION; ENVIRONMENTAL FACTOR; ERYTHROPOIESIS; EXTRAMEDULLARY HEMATOPOIESIS; FERRITIN BLOOD LEVEL; HEMOCHROMATOSIS; HUMAN; HYPERCOAGULABILITY; IRON ABSORPTION; IRON CHELATION; IRON OVERLOAD; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAGNETISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; THALASSEMIA; THALASSEMIA INTERMEDIA; UPREGULATION;

CHELATION THERAPY; HUMANS; INTESTINAL ABSORPTION; IRON CHELATING AGENTS; IRON OVERLOAD; IRON, DIETARY; THALASSEMIA;

EID: 84876713390     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23405     Document Type: Article

References (96)

1. Fucharoen S, Ketvichit P, Pootrakul P, et al. Clinical manifestation of beta-thalassemia/hemoglobin E disease. J Pediatr Hematol Oncol 2000;22:552-557.
2. Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: A comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005;127:1523-1530.
3. Fucharoen S, Winichagoon P. New updating into hemoglobinopathies. Int J Lab Hematol 2012; doi: 10.1111/j.1751-553x.2012.01446.x. [Epub ahead of print]
4. Sripichai O, Makarasara W, Munkongdee T, et al. A scoring system for the classification of beta-thalassemia/Hb E disease severity. Am J Hematol 2008;83:482-484.
5. Fucharoen S, Winichagoon P. Hemoglobinopathies in Southeast Asia. Hemoglobin 1987;11:65-88.
6. Tso SC, Loh TT, Todd D. Iron overload in patients with haemoglobin H disease. Scand J Haematol 1984;32:391-394.
7. Viprakasit V, Tanphaichitr VS, Mahasandana C, et al. Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens. J Med Assoc Thai 2001;84:929-941.
8. Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev 2012;26:S3-S6.
9. Lorey F, Cunningham G, Vichinsky EP, et al. Universal newborn screening for Hb H disease in California. Genet Test 2001;5:93-100.
10. Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 2009;52:486-490.
11. Musallam KM, Taher AT, Rachmilewitz EA. beta-Thalassemia intermedia: A clinical perspective. Cold Spring Harb Perspect Med 2012;2:a013482.
12. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. 4th ed. Oxford, UK Blackwell Science; 2001.
13. Vichinsky E. Hemoglobin E syndromes. Hematol Am Soc Hematol Educ Program 2007;79-83.
14. Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis 2010;5:13.
15. Lal A, Goldrich ML, Haines DA, et al. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med 2011;364:710-718.
16. Laosombat V, Viprakasit V, Chotsampancharoen T, et al. Clinical features and molecular analysis in Thai patients with HbH disease. Ann Hematol 2009;88:1185-1192.
17. Viprakasit V, Tanphaichitr VS, Pung-Amritt P, et al. Clinical phenotypes and molecular characterization of Hb H-Pakse disease. Haematologica 2002;87:117-125.
18. Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012;120:970-977.
19. Pippard MJ, Callender ST, Warner GT, et al. Iron absorption and loading in b-thalassaemia intermedia. Lancet 1979;2:819-821.
20. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in b-thalassemia major. Blood 2008;111:583-587.
21. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study. Eur J Haematol 2008;80:168-176.
22. Taher A, El Rassi F, Isma'eel H, et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008;93:1584-1586.
23. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in b-thalassemia. Haematologica 2007;92:583-588.
24. Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer 2007;49:329-332.
25. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
26. Au WY, Lam WW, Chu WW, et al. Organ-specific hemosiderosis and functional correlation in Chinese patients with thalassemia intermedia and hemoglobin H disease. Ann Hematol 2009;88:947-950.
27. Mavrogeni S, Gotsis E, Ladis V, et al. Magnetic resonance evaluation of liver and myocardial iron deposition in thalassemia intermedia and b-thalassemia major. Int J Cardiovasc Imaging 2008;24:849-854.
28. Origa R, Barella S, Argiolas GM, et al. No evidence of cardiac iron in 20 never or minimally transfused patients with thalassemia intermedia. Haematologica 2008;93:1095-1096.
29. Roghi A, Cappellini MD, Wood JC, et al. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: An MRI T2* study. Ann Hematol 2010;89:585-589.
30. Taher AT, Musallam KM, Wood JC, et al. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol 2010;85:288-290.
31. Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: Reassessment of iron chelation strategies. Br J Haematol 2009;147:634-640.
32. Fiorelli G, Fargion S, Piperno A, et al. Iron metabolism in thalassemia intermedia. Haematologica 1990;75:89-95.
33. Pootrakul P, Kitcharoen K, Yansukon P, et al. The effect of erythroid hyperplasia on iron balance. Blood 1988;71:1124-1129.
34. Tanno T, Miller JL. Iron Loading and overloading due to ineffective erythropoiesis. Adv Hematol 2010;2010:358283.
35. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811-7819.
36. Ganz T. Hepcidin and iron regulation, 10 years later. Blood 2011;117:4425-4433.
37. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
38. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037-1044.
39. Musallam KM, Taher AT, Duca L, et al. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with beta thalassemia intermedia. Blood Cells Mol Dis 2011;47:232-234.
40. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-1101.
41. Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009;114:181-186.
42. Casanovas G, Vujic SM, Casu C, et al. The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica 2012; doi: 10.3324/haematol.2012.069807. [Epub ahead of print].
43. Fucharoen S, Weatherall DJ. The hemoglobin E thalassemias. Cold Spring Harb Perspect Med 2012;2.
44. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: Revisited. Blood Cells Mol Dis 2006;37:12-20.
45. Musallam KM, Taher AT, Rachmilewitz EA. +-Thalassemia intermedia: A clinical perspective. Cold Spring Harbor Perspectives Med 2012;2.
46. Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The OPTIMAL CARE study. Blood 2010;115:1886-1892.
47. Olivieri NF. Treatment strategies for hemoglobin E beta-thalassemia. Blood Rev 26, S28-S30. 2012. Ref Type: Abstract.
48. Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol 2010;150:486-489.
49. Musallam KM, Motta I, Salvatori M, et al. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with +-thalassemia intermedia. Blood Cells Mol Dis 1915;49:136-139.
50. Mancuso A, Sciarrino E, Renda MC, et al. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin 2006;30:119-124.
51. Restivo PG, Renda D, Valenza F, et al. Hepatocellular carcinoma in patients with thalassaemia syndromes: Clinical characteristics and outcome in a long term single centre experience. Br J Haematol 2010;150:245-247.
52. Elmberg M, Hultcrantz R, Ekbom A, et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003;125:1733-1741.
53. Prati D, Maggioni M, Milani S, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent b-thalassemia. A multicenter study of 117 cases. Haematologica 2004;89:1179-1186.
54. Borgna-Pignatti C, De Stefano P, Sessa F, et al. Hepatocellular carcinoma in thalassemia major. Med Pediatr Oncol 1986;14:327-328.
55. Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica 2011;96:1605-1612.
56. Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006;135:574-582.
57. Li GF, Pan YZ, Sirois P, et al. Iron homeostasis in osteoporosis and its clinical implications. Osteoporos Int 2012;23:2403-2408.
58. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, et al. Bone histomorphometry in children and adolescents with +-thalassemia disease: Iron-associated focal osteomalacia. J Clin Endocrinol Metabolism 2003;88:3966-3972.
59. Musallam KM, Beydoun A, Hourani R, et al. Brain magnetic resonance angiography in splenectomized adults with beta-thalassemia intermedia. Eur J Haematol 2011;87:539-546.
60. Musallam KM, Nasreddine W, Beydoun A, et al. Brain positron emission tomography in splenectomized adults with beta-thalassemia intermedia: Uncovering yet another covert abnormality. Ann Hematol 2012;91:235-241.
61. Finch CA, Bellotti V, Stray S, et al. Plasma ferritin determination as a diagnostic tool. West J Med 1986;145:657-663.
62. Jacobs A, Miller F, Worwood M, et al. Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. Br Med J 1972;4:206-208.
63. Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995;332:918-922.
64. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993;42:81-85.
65. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68, 276 biopsies. J Hepatol 1986;2:165-173.
66. Ambu R, Crisponi G, Sciot R, et al. Uneven hepatic iron and phosphorus distribution in beta-thalassemia. J Hepatol 1995;23:544-549.
67. Villeneuve J-P, Bilodeau M, Lepage R, et al. Variability in hepatic iron concentration measurement from needle-biopsy specimens. J Hepatol 1996;25:172-177.
68. Emond MJ, Bronner MP, Carlson TH, et al. Quantitative study of the variability of hepatic iron concentrations. Clin Chem 1999;45:340-346.
69. Butensky E, Fischer R, Hudes M, et al. Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. Am J Clin Pathol 2005;123:146-152.
70. Hankins JS, McCarville MB, Loeffler RB, et al. R2* magnetic resonance imaging of the liver in patients with iron overload. Blood 2009;113:4853-4855.
71. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005;106:1460-1465.
72. St Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-861.
73. Voskaridou E, Douskou M, Terpos E, et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol 2004;126:736-742.
74. Dixon RM, Styles P, al-Refaie FN, et al. Assessment of hepatic iron overload in thalassemic patients by magnetic resonance spectroscopy. Hepatology 1994;19:904-910.
75. Cheng HL, Holowka S, Moineddin R, et al. Liver iron overload assessment by T *2 magnetic resonance imaging in pediatric patients: An accuracy and reproducibility study. Am J Hematol 2012;87:435-437.
76. Saiviroonporn P, Viprakasit V, Sanpakit K, et al. Intersite validations of the pixel-wise method for liver R2* analysis in transfusion-dependent thalassemia patients: A more accessible and affordable diagnostic technology. Hematol Oncol Stem Cell Ther 2012;5:91-95.
77. Wood JC. Impact of iron assessment by MRI. Hematology Am Soc Hematol Educ Program 2011;2011:443-450.
78. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-2179.
79. Sheth S. SQUID biosusceptometry in the measurement of hepatic iron. Pediatr Radiol 2003;33:373-377.
80. Cossu P, Toccafondi C, Vardeu F, et al. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur J Pediatr 1981;137:267-271.
81. Akrawinthawong K, Chaowalit N, Chatuparisuth T, et al. Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. Hematology 2011;16:113-122.
82. Chan JC, Chim C-S, Ooi CG, et al. Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease. Br J Haematol 2006;133:198-205.
83. Ladis V, Berdousi H, Gotsis E, et al. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. Br J Haematol 2010;151:504-508.
84. Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003;122:305-310.
85. Pippard MJ, Weatherall DJ. Iron balance and the management of iron overload in b-thalassemia intermedia. Birth Defects Orig Artic Ser 1988;23:29-33.
86. Voskaridou E, Douskou M, Plata E, et al. Treatment with deferasirox effectively decreases iron burden in patients with sickle cell syndromes. Haematologica 2009;94:abst 215.
87. Trachtenberg F, Vichinsky E, Haines D, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol 2011;86:433-436.
88. Voskaridou E, Plata E, Douskou M, et al. Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: Results of a pilot study. Br J Haematol 2010;148:332-334.
89. Rombos Y, Tzanetea R, Konstantopoulos K, et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 2000;85:115-117.
90. Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992;79:2741-2748.
91. Taher AT, Porter J, Viprakasit V, et al. Estimation of liver iron concentration by serum ferritin measurement in non-transfusion-dependent thalassemia patients: Analysis from the 1-year THALASSA study. Haematogica 2012;97:383.
92. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program 2001;47-61.
93. Musallam KM, Cappellini MD, Taher AT. Evaluation of the 5 mg/g liver iron concentration threshold and its association with vascular and endocrine/bone morbidity in b-thalassemia intermedia. Blood 2012;120:abs. 1024.
94. Nuttall KL, Palaty J, Lockitch G. Reference limits for copper and iron in liver biopsies. Ann Clin Lab Sci 2003;33:443-450.
95. Bush VJ, Moyer TP, Batts KP, et al. Essential and toxic element concentrations in fresh and formalin-fixed human autopsy tissues. Clin Chem 1995;41:284-294.
96. Thalassaemia International Federation. Guidelines for the clinical management of thalassaemia, 2nd Revised Edition. Available at: http://www thalassaemia org cy/pdf/Guidelines_2nd_revised_edition_EN pdf 2008.